Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (201-210 of 380) with videos related to

Pageof 38
Sort By:
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
Blood|July 10, 2008
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myelomaLaura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, et al.
Bone Marrow Transplantation|June 18, 2024
Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working partyHélène Schoemans, Linda J Burns, Sarah J Liptrott, et al.
Bone Marrow Transplantation|April 15, 2025
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma GroupCarmen Martínez, Irma Khvedelidze, Mathilde Fekom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Genetic abnormalities and patterns of antigenic expression in multiple myelomaGema Mateo, Mariana Castellanos, Ana Rasillo, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2017
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationCarmen Martínez, Jorge Gayoso, Carmen Canals, et al.
Bone Marrow Transplantation|May 19, 2022
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022John A Snowden, Isabel Sánchez-Ortega, Selim Corbacioglu, et al.
Pageof 38

Showing results (201-210 of 380) with videos related to

Sort By:
Pageof 38
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
Blood|July 10, 2008
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myelomaLaura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, et al.
Bone Marrow Transplantation|June 18, 2024
Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working partyHélène Schoemans, Linda J Burns, Sarah J Liptrott, et al.
Bone Marrow Transplantation|April 15, 2025
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma GroupCarmen Martínez, Irma Khvedelidze, Mathilde Fekom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Genetic abnormalities and patterns of antigenic expression in multiple myelomaGema Mateo, Mariana Castellanos, Ana Rasillo, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2017
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationCarmen Martínez, Jorge Gayoso, Carmen Canals, et al.
Bone Marrow Transplantation|May 19, 2022
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022John A Snowden, Isabel Sánchez-Ortega, Selim Corbacioglu, et al.
Pageof 38